Report #2830652

Received Mar 11, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: 50 yrs
State: TX
Recovered: Recovered
Vaccinated: Dec 4, 2024
Onset: Dec 4, 2024
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	1	KB2YT	LA

Symptoms (1)

Injection site rash

Symptom narrative

Skin Rash at injection site; This non-serious case was reported by a other health professional via sales rep and described the occurrence of injection site rash in a 50-year-old female patient who received Herpes zoster (Shingrix) (batch number KB2YT) for prophylaxis. On 04-DEC-2024, the patient received the 1st dose of Shingrix (left deltoid). On 04-DEC-2024, less than a day after receiving Shingrix, the patient experienced injection site rash (Verbatim: Skin Rash at injection site). On 11-DEC-2024, the outcome of the injection site rash was resolved (duration 7 days). The reporter considered the injection site rash to be related to Shingrix. The company considered the injection site rash to be related to Shingrix. Additional Information: GSK Receipt Date: 04-MAR-2025 The healthcare professional reported that the patient received the 1st dose of Shingrix and experienced skin rash at injection site. The patient was not on other products. This was not related to an existing case. The healthcare professional did not have consent to contact.